While SGT-53 and similar therapies have primarily been tested in solid tumors, the underlying mechanisms of p53-driven apoptosis and cell cycle regulation are highly relevant to hematologic cancers such as leukemia and lymphoma [653, 654]. This evidence concerns the gene TP53 and lymphoma.